AlphaTON Capital Corp (Nasdaq: ATON) (“AlphaTON”) and its wholly-owned oncology subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (“Cyncado”), today announced a poster presentation at the annual meeting of the Society for Immunotherapy of Cancer, to be held November 5-9, 2025 in National Harbor, Maryland. The poster reports preclinical results from work conducted by National Cancer Institute (NCI) investigators in NCI laboratories. In these studies, NCI researchers evaluated combinations of selective adenosine A2B antagonism (TT-4) and A2A antagonism (TT-10) with antigen-specific cancer vaccines.
Experiments in three mouse models of therapeutic cancer vaccines, conducted by researchers at the Vaccine Branch of the National Cancer Institute in Bethesda, Maryland, support the conclusion that strategies optimized to inhibit adenosine A2B and A2A receptor-mediated immune suppression can synergize with tumor-specific therapeutic vaccines to provide a robust antitumor immune response that should be translatable to humans. Synergy was observed in the TC1 lung cancer model using a triple combination of co-administered TT-4, a selective A2B receptor antagonist, and TT-10, a selective A2A receptor antagonist, as well as a therapeutic E7 peptide vaccine. This triple combination significantly suppressed tumor growth, improved survival, and elicited specific intratumoral CD8+ T cell responses. Notably, several mice receiving this combination showed complete tumor regression and were resistant to further tumor challenge without the addition of checkpoint inhibitors. Therapeutic synergy was confirmed in two additional mouse models: the CT26 colon cancer model using irradiated CT26 cells as a whole cell vaccine and the poorly immunogenic B16F10 melanoma model administered a gp100 peptide vaccine.
“This collaboration with NCI investigators reflects a multi-year effort to define how co-administration of selective A2B and A2A receptor antagonists can amplify vaccine-induced immunity,” said Robert Kramer, PhD, chief scientific officer of Cyncado Therapeutics. “Dose escalation of TT-10 in patients with solid tumors is almost complete, and we are preparing to administer TT-4 to the first patient in our planned mesothelioma trial, with the goal of prioritizing indications where these investigational drugs can have the greatest impact.
“At AlphaTON, one of our strategic goals is to combine disciplined digital infrastructure with rigorous life sciences programs,” said Brittany Kaiser, Managing Director of AlphaTON Capital. “This preclinical data strengthens our thesis on adenosine biology and guides how we deploy capital and partnerships to advance TT-4 and TT-10 into the clinic.” »
Clinical Program Status
-
TT-4 (A2BR antagonist): IND-enabled program, with mesothelioma as primary indication, preparing for administration to the first patient in the first quarter of 2026 under the company’s existing protocol.
-
TT-10 (A2AR antagonist): Phase 1 dose escalation underway in advanced solid tumors
SITC Poster Details
-
Title: Cancer vaccines act synergistically with adenosine inhibitors to improve survival and delay tumor progression in in vivo lung, colon, and melanoma cancer models
-
Session: Poster room
-
Summary number: 662
-
Date and time: Saturday November 8, 2025
Acknowledgments and Disclaimers Related to NCI
This work was conducted by researchers at the National Cancer Institute at NCI Laboratories as part of a multi-year project. Research and Development Cooperation Agreement No. 03442. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Cancer Institute. Mention of commercial products does not imply endorsement by the United States Government.
About AlphaTON Capital Corp.
AlphaTON Capital is a digital asset treasury company focused on creating and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The company implements a comprehensive treasury strategy that combines direct token acquisition, validation operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, AlphaTON Capital provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram’s billion-user platform while maintaining the governance standards and reporting transparency of a Nasdaq-listed company.
Led by Managing Director Brittany Kaiser and Chief Investment Officer Enzo Villani, the company’s activities span network validation and staking operations, Telegram-based application development, and strategic investments in TON-based decentralized financial protocols, gaming platforms, and commercial applications. AlphaTON Capital Corp is headquartered in the British Virgin Islands and is listed on Nasdaq under the symbol ATON.
AlphaTON Capital, through its legacy businesses, is also advancing first-in-class therapies that target known checkpoint resistance pathways to achieve a durable therapeutic response and improve patients’ quality of life. AlphaTON Capital actively engages in the drug development process and provides strategic advice to guide the development of new immunotherapy assets and combinations of assets.
About Cyncado Therapeutics
Tarus Therapeutics, LLC (doing business as Cyncado Therapeutics), a wholly owned subsidiary of AlphaTON Capital Corp, is currently developing potentially best-in-class small molecule adenosine receptor antagonists targeting A2B and A2A receptors to overcome immune suppression in oncology. The Company’s lead program, TT-4, is an ultra-selective oral A2B receptor antagonist, initially focused on mesothelioma, and is expected to be administered to the first patient in the first quarter of 2026. Cyncado is also developing dual-antagonist strategies designed to achieve complete blockade of adenosine-mediated immune evasion, potentially unlocking synergistic anti-tumor effects and durable patient responses.
Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including statements regarding the Company’s business strategy, plans and objectives, future operations, exploration of tokenization frameworks, clinical development timelines, potential decentralized science applications (DeSci), growth of the TON ecosystem, therapeutic development results, regulatory approvals, financing activities and statements preceded, followed by or including words such as “believe”, “expects”, “anticipates”, “a “intend”, “estimate”, “will”, “may”, “plans”, “potential”, “objectives” or similar expressions are forward-looking statements.
These forward-looking statements are subject to significant risks and uncertainties, including, but not limited to: risks that tokenization or DeSci frameworks may not be successfully pursued or implemented; uncertainty regarding the ability of the Company and Cyncado to enter into definitive agreements on reasonable terms; uncertainty regarding clinical trial results and regulatory approvals; the uncertainty of the Company’s investment in TON and digital assets; regulatory and legal risks associated with digital assets and tokenization; risks related to the Telegram platform and the TON ecosystem; market volatility; competitive risks in digital assets and therapeutic product development; ability to attract and retain key personnel; the ability of the Company to meet its debt service obligations and honor its commitments; macroeconomic conditions; and other factors described in “Item 3 – Key Information – Risk Factors” in the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2025, and subsequent reports filed with the Securities and Exchange Commission.
Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, actual results may differ materially. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
Contact details
Investor Relations
AlphaTON Capital Corp.
(email protected)
(203) 682-8200
Media inquiries
Richard Laermer
RP RLM
(email protected)
(212) 741-5106 ext. 216
